<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We examined the effects of the preferential cyclooxygenase-2 (COX-2) inhibitor <z:chebi fb="0" ids="41423">celecoxib</z:chebi> on <z:mp ids='MP_0002006'>tumorigenesis</z:mp>, <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, vascular endothelial growth factor (VEGF) protein expression and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> in HT-29 human colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cell xenografts in <z:mp ids='MP_0003815'>nude</z:mp> mouse rectum </plain></SENT>
<SENT sid="1" pm="."><plain>COX-2 mRNA expression was examined in the xenograft and metastatic sites </plain></SENT>
<SENT sid="2" pm="."><plain>The antitumor effect of <z:chebi fb="0" ids="41423">celecoxib</z:chebi> in the xenografts was evaluated by measuring the weight of the peri-ano-<z:e sem="disease" ids="C1527408,C0034885" disease_type="Disease or Syndrome;Neoplastic Process" abbrv="">rectal tumor</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The anti-metastatic effect of <z:chebi fb="0" ids="41423">celecoxib</z:chebi> was assessed by quantification of lymph node and <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">lung metastases</z:e> by amplification of a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related human DNA by TaqMan PCR </plain></SENT>
<SENT sid="4" pm="."><plain>The effects of <z:chebi fb="0" ids="41423">celecoxib</z:chebi> on <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, <z:chebi fb="0" ids="15551">prostaglandin E2</z:chebi> (<z:chebi fb="0" ids="15551">PGE2</z:chebi>) production and VEGF protein expression in the xenografts were evaluated by means of microvessel density (MVD) counting, terminal deoxynucleotidyl transferase-mediated nick end labeling assay, quantitative enzyme-linked immunosorbent assay and western blotting, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>The rectal <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e> showed lymph node and <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">lung metastases</z:e> with enhanced expression of COX-2 mRNA in each organ </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="41423">Celecoxib</z:chebi> inhibited rectal xenograft growth in a dose-dependent manner as follows: 150 ppm, 33.0% (p=0.000220); 750 ppm, 46.4% (p=0.0000292); 1500 ppm, 63.4% (p=0.0000109) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="41423">Celecoxib</z:chebi> inhibited lymph node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> in a dose-dependent manner as follows: 150 ppm, 86.7% (p=0.0263); 750 ppm, 90.3% (p=0.00638); 1500 ppm, 96.0% (p=0.000894) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="41423">Celecoxib</z:chebi> also inhibited lung <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> as follows: 750 ppm, 53.3% (p=0.0107); 1500 ppm, 78.3% (p=0.00022) </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="41423">Celecoxib</z:chebi> (1500 ppm) significantly inhibited <z:chebi fb="0" ids="15551">PGE2</z:chebi> production by 68.4% (p=0.000157) and MVD counting by 48.2% (p=1.3x10-12) and induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> 2.5-fold (p=3.0x10-14) in the rectal xenograft </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="41423">Celecoxib</z:chebi> suppressed VEGF protein expression in the rectal xenograft </plain></SENT>
<SENT sid="11" pm="."><plain>These studies demonstrate that <z:chebi fb="0" ids="41423">celecoxib</z:chebi> reduces the growth and metastatic potential of colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> in mice through COX-2 inhibition, anti-<z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> induction </plain></SENT>
<SENT sid="12" pm="."><plain>The studies using HT-29 human colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> cell xenografts in <z:mp ids='MP_0003815'>nude</z:mp> mouse rectum also provide important information that supports that the COX-2 inhibitor <z:chebi fb="0" ids="41423">celecoxib</z:chebi> has a high potential for use as a clinical agent for inhibition of hematological and <z:e sem="disease" ids="C0024232" disease_type="Neoplastic Process" abbrv="">lymphatic metastases</z:e> of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>